Sunzen Biotech Bhd
Sunzen Group Berhad, an investment holding company, engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. It operates through Human Health, Medical Devices and Services, and Loan Financing segments. The company provides veterinary, pharmaceutical, chemical products, animal health, … Read more
Sunzen Biotech Bhd (0148) - Total Assets
Latest total assets as of March 2024: RM159.04 Million MYR
Based on the latest financial reports, Sunzen Biotech Bhd (0148) holds total assets worth RM159.04 Million MYR as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sunzen Biotech Bhd - Total Assets Trend (2016–2023)
This chart illustrates how Sunzen Biotech Bhd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sunzen Biotech Bhd - Asset Composition Analysis
Current Asset Composition (December 2023)
Sunzen Biotech Bhd's total assets of RM159.04 Million consist of 33.6% current assets and 66.4% non-current assets.
| Asset Category | Amount (MYR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM0.00 | 12.6% |
| Accounts Receivable | RM14.79 Million | 8.7% |
| Inventory | RM9.47 Million | 5.6% |
| Property, Plant & Equipment | RM0.00 | 0.0% |
| Intangible Assets | RM0.00 | 0.0% |
| Goodwill | RM0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how Sunzen Biotech Bhd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunzen Biotech Bhd's current assets represent 33.6% of total assets in 2023, a decrease from 66.8% in 2016.
- Cash Position: Cash and equivalents constituted 12.6% of total assets in 2023, down from 47.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 8.7% of total assets.
Sunzen Biotech Bhd Competitors by Total Assets
Key competitors of Sunzen Biotech Bhd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
Sunzen Biotech Bhd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Sunzen Biotech Bhd generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sunzen Biotech Bhd generates $ 2.90 in net profit.
Sunzen Biotech Bhd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.71 | 6.00 | 3.82 |
| Quick Ratio | 5.57 | 4.57 | 3.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RM45.83 Million | RM 33.62 Million | RM 57.85 Million |
Sunzen Biotech Bhd - Advanced Valuation Insights
This section examines the relationship between Sunzen Biotech Bhd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 12.8% |
| Total Assets | RM170.35 Million |
| Market Capitalization | $13.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sunzen Biotech Bhd's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sunzen Biotech Bhd's assets grew by 12.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sunzen Biotech Bhd (2016–2023)
The table below shows the annual total assets of Sunzen Biotech Bhd from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | RM170.35 Million | +12.85% |
| 2022-12-31 | RM150.96 Million | +1.51% |
| 2021-12-31 | RM148.71 Million | +20.70% |
| 2020-12-31 | RM123.20 Million | -3.99% |
| 2019-12-31 | RM128.32 Million | -13.04% |
| 2018-12-31 | RM147.57 Million | +23.86% |
| 2017-12-31 | RM119.15 Million | +12.18% |
| 2016-12-31 | RM106.21 Million | -- |